Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Subscribe To Our Newsletter & Stay Updated
